Viemed Healthcare (NASDAQ:VMD) Stock Gets Price Target Cut from Freedom Broker

Viemed Healthcare (NASDAQ:VMD) had its target price lowered by research analysts at Freedom Broker from $11.00 to $10.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Freedom Broker‘s target price would indicate a potential upside of 11.67% from the stock’s previous close.

VMD has been the topic of a number of other reports. Wall Street Zen upgraded Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings lowered shares of Viemed Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. Barrington Research assumed coverage on shares of Viemed Healthcare in a report on Monday, August 24th. They issued an “outperform” rating and a $14.00 price objective on the stock. Finally, Freedom Capital downgraded shares of Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Viemed Healthcare Stock Performance

Shares of NASDAQ VMD traded down $0.17 during mid-day trading on Monday, hitting $8.96. The company had a trading volume of 195,970 shares, compared to its average volume of 284,573. The stock has a market cap of $339.33 million, a price-to-earnings ratio of 23.51, a PEG ratio of 2.21 and a beta of 1.05. Viemed Healthcare has a 12 month low of $6.18 and a 12 month high of $12.61. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.25 and a quick ratio of 1.16. The firm’s 50 day simple moving average is $9.26 and its two-hundred day simple moving average is $9.59.

Viemed Healthcare (NASDAQ:VMD) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). The company had revenue of $80.67 million for the quarter, compared to analyst estimates of $80.78 million. Viemed Healthcare had a net margin of 5.03% and a return on equity of 10.64%. As a group, equities research analysts forecast that Viemed Healthcare will post 0.41 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of VMD. Covestor Ltd acquired a new position in shares of Viemed Healthcare during the third quarter valued at $28,000. Signaturefd LLC raised its stake in shares of Viemed Healthcare by 64.0% during the third quarter. Signaturefd LLC now owns 4,939 shares of the company’s stock valued at $45,000 after purchasing an additional 1,927 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in Viemed Healthcare by 49.8% in the third quarter. State of Alaska Department of Revenue now owns 5,145 shares of the company’s stock worth $46,000 after purchasing an additional 1,711 shares during the period. Globeflex Capital L P acquired a new stake in Viemed Healthcare in the second quarter worth about $86,000. Finally, Legal & General Group Plc acquired a new stake in Viemed Healthcare in the second quarter worth about $97,000. Institutional investors own 74.24% of the company’s stock.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a U.S. healthcare company that provides in-home medical equipment and clinical services for patients with chronic respiratory and other complex medical conditions. Its services are designed to help patients receive care at home while supporting hospitals and clinicians in managing ongoing conditions.

The company’s offerings include non-invasive ventilation, oxygen therapy, sleep-apnea equipment, respiratory therapy, remote patient monitoring and related durable medical equipment.